Targeting SHP2-dependent adaptive resistance to braf and mek inhibition in gliomasoneneuro speaker series: red, green, blue-and motion too
Abiola Abdulrahman Ayanlaja, Ph.D. from the Schrek Lab discusses targeting SHP2-dependent adaptive resistance to BRAF and MEK inhibition in gliomas
Abiola Abdulrahaman Ayanlaja, Ph.D.
Postdoctoral Researcher
School of Medicine (SOM)
Neuro-Oncology